Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00946270 | Pomalidomide for Myelofibrosis Patients | completed | Phase 2 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2019 | clinicaltrials |
| NCT01294618 | Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia(NILOPEG) | completed | Phase 2 | 60 | Hospices Civils de LyonOTHER | 1 | May 28, 2019 | clinicaltrials |
| NCT00895934 | Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2019 | clinicaltrials |
| NCT00414310 | Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 153 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT00475020 | Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome | completed | Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT02311569 | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | completed | Phase 2 | 39 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT00413166 | All-trans Retinoic Acid, and Arsenic +/- Idarubicin | completed | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT01392989 | Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders | completed | Phase 2 | 44 | Everett MeyerOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT01175785 | Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | completed | Phase 2 | 15 | Nohla Therapeutics, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02076191 | Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML | completed | Phase 1 / Phase 2 | 49 | John MascarenhasOTHER | 1 | Feb 28, 2019 | clinicaltrials |
| NCT00416598 | Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 546 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2019 | clinicaltrials |
| NCT00766116 | Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 50 | University of California, San DiegoOTHER | 1 | Feb 18, 2019 | clinicaltrials |
| NCT01687387 | Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)(EFFIKIR) | completed | Phase 2 | 152 | Innate PharmaINDUSTRY | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01729845 | Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 7, 2019 | clinicaltrials |
| NCT01807598 | Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia | completed | Phase 2 | 10 | Jason Robert GotlibOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT02296242 | Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 53 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01408563 | Reduced Intensity Double Umbilical Cord Blood Transplantation | completed | Phase 2 | 33 | Massachusetts General HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02208037 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | completed | Phase 2 | 279 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02019069 | CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 11 | Rondeep BrarOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01720264 | Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant | completed | Phase 2 | 15 | Sherif S. FaragOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00840346 | Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)(PANOBIDARA) | completed | Phase 1 / Phase 2 | 46 | PETHEMA FoundationOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT00709592 | Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT | completed | Phase 2 | 42 | Virginia Commonwealth UniversityOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT00065143 | Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00038597 | Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML) | completed | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2018 | clinicaltrials |
| NCT01734304 | DC Vaccination for Postremission Therapy in AML | completed | Phase 1 / Phase 2 | 13 | Ludwig-Maximilians - University of MunichOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT01025154 | Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction | completed | Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01621724 | WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study | completed | Phase 1 / Phase 2 | 7 | Cell Medica LtdINDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02550535 | A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients | completed | Phase 1 / Phase 2 | 3 | Cell Medica LtdINDUSTRY | 3 | Oct 2, 2018 | clinicaltrials |
| NCT02282215 | Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia | completed | Phase 2 | 163 | Cellerant TherapeuticsINDUSTRY | 1 | Sep 27, 2018 | clinicaltrials |
| NCT00061581 | Experimental Bone Marrow Transplant Protocol | completed | Phase 2 | 14 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00233454 | Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia | completed | Phase 2 | 26 | Jason Robert GotlibOTHER | 1 | Sep 20, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01422603 | Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | completed | Phase 1 / Phase 2 | 9 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00134017 | Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer | completed | Phase 2 | 142 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT01602952 | Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI | completed | Phase 1 / Phase 2 | 85 | Il-Yang Pharm. Co., Ltd.INDUSTRY | 3 | Aug 29, 2018 | clinicaltrials |
| NCT01253447 | AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT00422591 | Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) | completed | Phase 2 | 175 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT00542971 | Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) | completed | Phase 1 / Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT01534260 | Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype | completed | Phase 1 / Phase 2 | 37 | Hamid SayarOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT00795002 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2018 | clinicaltrials |
| NCT01452646 | Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia(AML1310) | completed | Phase 2 | 515 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Aug 6, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00467961 | Stem Cell Transplantation for Patients With Cancers of the Blood | completed | Phase 2 | 61 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 13, 2018 | clinicaltrials |
| NCT01517035 | Improving Blood Stem Cell Collection and Transplant Procedures | completed | Phase 1 / Phase 2 | 43 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00890929 | Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 45 | Stanford UniversityOTHER | 1 | Jun 18, 2018 | clinicaltrials |
| NCT00611247 | Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia | completed | Phase 2 | 42 | Bruno C. MedeirosOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT00070135 | Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission | completed | Phase 2 | 121 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT01994837 | A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 32 | AbbVieINDUSTRY | 0 | Jun 6, 2018 | clinicaltrials |
| NCT02210858 | Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders | completed | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jun 10, 2019source: clinicaltrials